Jeil Pharm (002620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jeil Pharm (002620) has a cash flow conversion efficiency ratio of 0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩447.08 Million ≈ $302.98K USD) by net assets (₩475.12 Billion ≈ $321.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002620 net asset quality score to measure how much of total assets are equity-financed.
Jeil Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Jeil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Jeil Pharm (002620) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Jeil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Super Dragon Technology Co Ltd
TW:9955
|
0.036x |
|
Forum Markets, Incorporated
NASDAQ:FRMM
|
-0.121x |
|
Alithya Group inc Class A
TO:ALYA
|
0.010x |
|
DOMESCO Medical Import Export JSC
VN:DMC
|
0.001x |
|
Inscobee
KO:006490
|
0.020x |
|
Brixton Metals Corporation
V:BBB
|
-0.553x |
|
IokCompany Co. Ltd
KQ:078860
|
0.005x |
|
Consolidated Construction Consortium Limited
NSE:CCCL
|
-0.260x |
Annual Cash Flow Conversion Efficiency for Jeil Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jeil Pharm from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 002620 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩469.12 Billion ≈ $317.91 Million |
₩390.26 Million ≈ $264.47K |
0.001x | -91.99% |
| 2024-12-31 | ₩437.40 Billion ≈ $296.42 Million |
₩4.54 Billion ≈ $3.08 Million |
0.010x | +194.59% |
| 2023-12-31 | ₩402.19 Billion ≈ $272.56 Million |
₩-4.42 Billion ≈ $-2.99 Million |
-0.011x | +77.84% |
| 2022-12-31 | ₩419.79 Billion ≈ $284.49 Million |
₩-20.80 Billion ≈ $-14.10 Million |
-0.050x | -284.97% |
| 2021-12-31 | ₩500.31 Billion ≈ $339.06 Million |
₩13.40 Billion ≈ $9.08 Million |
0.027x | +156.50% |
| 2020-12-31 | ₩499.28 Billion ≈ $338.36 Million |
₩-23.67 Billion ≈ $-16.04 Million |
-0.047x | -190.82% |
| 2019-12-31 | ₩483.04 Billion ≈ $327.35 Million |
₩25.22 Billion ≈ $17.09 Million |
0.052x | +996.58% |
| 2018-12-31 | ₩589.58 Billion ≈ $399.55 Million |
₩-3.43 Billion ≈ $-2.33 Million |
-0.006x | -116.75% |
| 2017-12-31 | ₩170.44 Billion ≈ $115.50 Million |
₩5.92 Billion ≈ $4.01 Million |
0.035x | -22.85% |
| 2016-12-31 | ₩252.08 Billion ≈ $170.83 Million |
₩11.36 Billion ≈ $7.70 Million |
0.045x | +296.38% |
| 2015-12-31 | ₩241.39 Billion ≈ $163.59 Million |
₩2.74 Billion ≈ $1.86 Million |
0.011x | +169.58% |
| 2012-12-31 | ₩241.41 Billion ≈ $163.60 Million |
₩-3.94 Billion ≈ $-2.67 Million |
-0.016x | -116.00% |
| 2011-12-31 | ₩231.40 Billion ≈ $156.81 Million |
₩23.63 Billion ≈ $16.01 Million |
0.102x | -- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more